Hamilton Named Medical Chief Of DOR BioPharma
The company said that Hamilton is a recognized expert in both the global development of topically active steroids as well as in Graft-versus-Host disease. He has had a career of more than 25 years in both academia and industry, most notably at Wyeth and Astra, USA.
In his new role, Hamilton will lead DOR's clinical affairs, with an emphasis on the execution of its confirmatory Phase 3 clinical trial of orBec in the treatment of acute GI GVHD.
Hamilton began his training in bone marrow transplantation while in medical school, with further training at the Children's Hospital Medical Center, Boston. His academic career, at the University of Washington and the University of Miami, focused on pediatric immunology and bone marrow transplantation. His research focus was in the immunobiology of GVHD in an animal model.
He also spent several years as chief of immunology at the Children's Hospital, Oakland, California with a clinical appointment on the Pediatric Bone Marrow Transplant Service at the University of California, San Francisco.
Following his academic career, Hamilton joined the pharmaceutical industry, initially at Astra, USA working on inhaled steroids for the treatment of allergic rhinitis and asthma, including three successful new drug applications for these products. He has worked with several pharmaceutical and biotechnology companies including Alkermes in multiple therapeutic areas, including allergy, asthma, oncology, rheumatology, hematology, diagnostics, and drug delivery systems.
Ewing, New Jersey-based DOR BioPharma is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.
DOR's lead product, orBec, is a locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR said it expects to begin a confirmatory Phase 3 clinical trial of orBec for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the first half of 2009.
OrBec is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation.
DOR also has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis. The company's Biodefense Division is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax.
FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .
Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .
Copyright(C)2009 by financialwire.net, Inc. All rights reserved.
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
